Systemic Sclerosis clinical trials at UC Irvine

2 research studies open to eligible people

Showing trials for

  • FT819 in B-cell Mediated Autoimmune Disease

    open to eligible people ages 12-70

    This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate-to-severe active systemic lupus erythematosus (SLE) with or without nephritis, antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.

    Irvine, California and other locations

  • NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

    open to eligible people ages 18-75

    This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

    Los Angeles, California and other locations

Our lead scientists for Systemic Sclerosis research studies include .

Last updated: